You just read:

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)

News provided by

Syndax Pharmaceuticals, Inc.

May 17, 2018, 07:00 ET